

Oncology Today with Dr Neil Love: Advances in Gynecologic Cancers from the 2022 ASCO Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. At ASCO 2022, which of the following results was reported with niraparib compared to placebo maintenance therapy among patients in the PRIME trial who had achieved a complete or partial response to first-line platinum-based chemotherapy?
 - a. Only patients who achieved a complete response with first-line chemotherapy derived a progression-free survival (PFS) benefit
 - b. Only patients who achieved a partial response with first-line chemotherapy derived a PFS benefit
 - c. A PFS benefit was reported with maintenance niraparib regardless of response to first-line chemotherapy
2. What is the molecular target of the antibody-drug conjugate tisotumab vedotin?
 - a. TROP2
 - b. Tissue factor
 - c. HER2
 - d. Folate receptor alpha
3. Which of the following was the most common Grade ≥ 3 ocular adverse event among patients in the SORAYA trial evaluating mirvetuximab soravtansine for recurrent ovarian cancer?
 - a. Keratopathy
 - b. Dry eye
 - c. Photophobia
 - d. Blurred vision
4. In an exploratory analysis of the KEYNOTE-775 trial, how did PFS2 (disease progression on next line of therapy after first progression) compare between patients with mismatch repair-proficient (pMMR) disease and the "all-comer" group of all patients who received lenvatinib/pembrolizumab or physician's choice of chemotherapy for advanced, platinum-resistant endometrial cancer?
 - a. Median PFS2 was significantly longer with lenvatinib/pembrolizumab in the all-comer group but not in the pMMR group
 - b. Median PFS2 was significantly longer with lenvatinib/pembrolizumab in the pMMR group but not in the all-comer group
 - c. Median PFS2 was significantly longer in both the pMMR group and the all-comer group
5. At ASCO 2022, which of the following overall survival (OS) results was reported from a subgroup analysis of the Phase III KEYNOTE-826 trial evaluating the addition of pembrolizumab to chemotherapy/bevacizumab for advanced cervical cancer?
 - a. Patients derived an OS benefit with the addition of pembrolizumab regardless of platinum use
 - b. Patients who received cisplatin derived a significant OS benefit from the addition of pembrolizumab, but patients who received carboplatin did not
 - c. Patients who received carboplatin had a significant OS benefit from the addition of pembrolizumab, but patients who received cisplatin did not